Go Pro
→ Porter flew 3,300 miles to investigate this system (From Porter & Company) (Ad)tc pixel Free ZJYL Stock Alerts

Jin Medical International (ZJYL) Financials

Jin Medical International logo
$2.06 +0.00 (+0.05%)
As of 12:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Jin Medical International

Annual Income Statements for Jin Medical International

This table shows Jin Medical International's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 2.63 2.41 4.77 8.79 1.84
Consolidated Net Income / (Loss)		 3.37 5.41 5.76 7.10 2.57
Net Income / (Loss) Continuing Operations		 3.37 5.61 6.28 7.71 3.18
Total Pre-Tax Income 		2.88 2.74 3.22 4.18 1.60
Total Operating Income		 2.63 2.13 2.87 3.64 0.61
Total Gross Profit		 6.36 6.20 6.78 9.50 6.04
Total Revenue		 21 38 40 47 41
Operating Revenue		 21 38 40 47 41
Total Cost of Revenue		 14 26 26 28 29
Operating Cost of Revenue		 14 26 26 28 29
Total Operating Expenses		 3.73 8.14 7.84 12 11
Selling, General & Admin Expense		 1.67 2.18 2.37 4.37 3.88
Research & Development Expense		 1.57 1.89 1.54 1.50 1.56
Other Operating Expenses / (Income)		 -0.06 4.07 3.92 5.86 5.44
Total Other Income / (Expense), net		 0.43 1.22 0.71 1.09 1.98
Interest & Investment Income		 - 0.18 0.18 0.47 0.79
Other Income / (Expense), net		 0.44 1.04 0.53 0.62 1.19
Income Tax Expense		 0.25 0.04 0.34 0.76 0.21
Net Income / (Loss) Attributable to Noncontrolling Interest		 - 0.00 0.00 -0.52 0.39
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - 1.50 0.49 -0.84 0.36
Basic Earnings per Share		 $0.02 $0.02 $0.02 $0.02 $0.01
Weighted Average Basic Shares Outstanding		 135M 135M 145.14M 156.47M 156.55M
Diluted Earnings per Share		 - $0.02 $0.02 $0.02 $0.01
Weighted Average Diluted Shares Outstanding		 - 135M 145.14M 156.47M 156.55M
Weighted Average Basic & Diluted Shares Outstanding		 - - 155.95M 156.55M 156.55M

Quarterly Income Statements for Jin Medical International

No quarterly income statements for Jin Medical International are available.

Annual Cash Flow Statements for Jin Medical International

This table details how cash moves in and out of Jin Medical International's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2021 2022 2023 2024 2025
Period end date 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Net Change in Cash & Equivalents		 2.01 1.12 2.29 1.21 -0.53
Net Cash From Operating Activities		 5.84 1.58 3.11 -1.21 2.90
Net Cash From Continuing Operating Activities		 5.84 1.58 3.11 -1.21 2.90
Net Income / (Loss) Continuing Operations		 2.63 2.71 2.88 3.42 1.38
Consolidated Net Income / (Loss)		 2.63 2.71 2.88 3.42 1.38
Depreciation Expense		 0.35 0.36 0.23 0.24 0.24
Non-Cash Adjustments To Reconcile Net Income		 -0.08 0.03 0.11 -0.09 0.06
Changes in Operating Assets and Liabilities, net		 2.94 -1.52 -0.11 -4.89 1.22
Net Cash From Investing Activities		 -1.07 -0.12 -7.73 -9.51 -11
Net Cash From Continuing Investing Activities		 -1.07 -0.12 -7.73 -9.51 -11
Purchase of Property, Plant & Equipment		 -0.04 -0.04 -0.11 -0.14 -6.63
Acquisitions		 - 0.00 0.00 -0.98 -0.50
Purchase of Investments		 -4.96 -5.28 -12 -21 -9.70
Sale of Property, Plant & Equipment		 0.00 0.00 0.01 0.00 0.00
Sale and/or Maturity of Investments		 4.15 5.20 4.43 13 6.04
Net Cash From Financing Activities		 -2.87 0.12 6.91 12 7.35
Net Cash From Continuing Financing Activities		 -2.87 0.12 6.91 12 7.35
Repayment of Debt		 -3.64 0.12 -5.89 -1.08 -12
Repurchase of Preferred Equity		 - 0.00 -1.21 - 0.00
Repurchase of Common Equity		 - - 0.00 0.00 -0.10
Issuance of Debt		 0.77 0.00 5.67 12 19
Issuance of Common Equity		 0.00 0.00 8.00 0.31 0.00
Other Financing Activities, net		 0.00 0.00 0.34 0.00 0.00
Cash Interest Paid		 0.37 0.00 0.01 0.24 0.41
Cash Income Taxes Paid		 0.00 0.05 0.14 0.21 0.56

Quarterly Cash Flow Statements for Jin Medical International

No quarterly cash flow statements for Jin Medical International are available.

Annual Balance Sheets for Jin Medical International

This table presents Jin Medical International's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024 2025
Period end date 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Total Assets		 21 33 46 53
Total Current Assets		 19 31 43 44
Cash & Equivalents		 4.79 6.93 8.14 7.46
Short-Term Investments		 2.28 9.77 19 22
Accounts Receivable		 4.12 8.47 8.56 5.91
Inventories, net		 6.72 5.05 5.17 4.92
Prepaid Expenses		 0.99 0.89 2.33 3.68
Plant, Property, & Equipment, net		 1.63 1.48 1.46 7.90
Total Noncurrent Assets		 0.41 0.31 1.52 1.33
Noncurrent Deferred & Refundable Income Taxes		 0.25 0.15 0.12 0.14
Other Noncurrent Operating Assets		 0.16 0.15 1.40 1.19
Total Liabilities & Shareholders' Equity		 21 33 46 53
Total Liabilities		 5.70 8.92 17 24
Total Current Liabilities		 5.70 8.92 17 24
Short-Term Debt		 0.00 4.11 11 19
Accounts Payable		 4.51 3.39 3.01 3.26
Accrued Expenses		 - 0.32 0.43 0.67
Current Deferred Revenue		 0.83 0.83 0.80 0.61
Current Deferred & Payable Income Tax Liabilities		 0.25 0.27 1.12 0.30
Other Current Liabilities		 0.12 0.00 0.47 0.11
Total Noncurrent Liabilities		 0.00 0.00 0.10 0.00
Other Noncurrent Operating Liabilities		 - 0.00 0.10 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 15 24 29 30
Total Preferred & Common Equity		 15 24 29 30
Total Common Equity		 15 24 29 30
Common Stock		 0.09 6.44 6.76 6.76
Retained Earnings		 14 17 20 21
Accumulated Other Comprehensive Income / (Loss)		 -0.91 -1.40 -0.56 -0.92
Other Equity Adjustments		 1.65 2.01 2.59 2.86
Noncontrolling Interest		 - 0.00 -0.26 -0.07

Quarterly Balance Sheets for Jin Medical International

No quarterly balance sheets for Jin Medical International are available.

Annual Metrics And Ratios for Jin Medical International

This table displays calculated financial ratios and metrics derived from Jin Medical International's official financial filings.

Metric 2021 2022 2023 2024 2025
Period end date 9/30/2021 9/30/2022 9/30/2023 9/30/2024 9/30/2025
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 84.84% 3.29% 18.57% -11.98%
EBITDA Growth		 0.00% 3.33% 2.38% 27.31% -55.78%
EBIT Growth		 0.00% 3.18% 6.96% 25.58% -57.90%
NOPAT Growth		 0.00% -12.56% 21.83% 16.12% -82.30%
Net Income Growth		 0.00% 60.65% 6.34% 23.27% -63.75%
EPS Growth		 0.00% 0.00% 6.34% 0.00% -50.00%
Operating Cash Flow Growth		 0.00% -72.95% 96.53% -138.87% 340.50%
Free Cash Flow Firm Growth		 0.00% 0.00% 89.03% 287.94% -510.65%
Invested Capital Growth		 0.00% 0.00% 39.51% 15.13% 43.17%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - -
Gross Margin		 30.64% 16.15% 17.11% 20.22% 14.61%
EBITDA Margin		 16.48% 9.21% 9.13% 9.80% 4.93%
Operating Margin		 12.67% 5.55% 7.23% 7.74% 1.47%
EBIT Margin		 14.81% 8.27% 8.56% 9.07% 4.34%
Profit (Net Income) Margin		 16.23% 14.10% 14.52% 15.10% 6.22%
Tax Burden Percent		 116.98% 197.37% 178.66% 169.60% 161.21%
Interest Burden Percent		 93.66% 86.43% 94.93% 98.16% 88.93%
Effective Tax Rate		 8.63% 1.32% 10.67% 18.26% 13.45%
Return on Invested Capital (ROIC)		 0.00% 51.49% 26.19% 24.27% 3.30%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -42.18% -6.32% -5.15% -12.30%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 19.57% 3.17% 2.75% 5.55%
Return on Equity (ROE)		 0.00% 71.06% 29.36% 27.02% 8.85%
Cash Return on Invested Capital (CROIC)		 0.00% -148.51% -6.80% 10.20% -32.20%
Operating Return on Assets (OROA)		 0.00% 15.15% 12.61% 10.83% 3.62%
Return on Assets (ROA)		 0.00% 25.85% 21.38% 18.03% 5.19%
Return on Common Equity (ROCE)		 0.00% 71.06% 29.36% 27.15% 8.90%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 35.53% 0.00% 24.63% 0.00%
Net Operating Profit after Tax (NOPAT)		 2.40 2.10 2.56 2.97 0.53
NOPAT Margin		 11.58% 5.48% 6.46% 6.33% 1.27%
Net Nonoperating Expense Percent (NNEP)		 0.00% 93.67% 32.51% 29.42% 15.60%
Return On Investment Capital (ROIC_SIMPLE)		 - 13.80% 9.12% 7.46% 1.09%
Cost of Revenue to Revenue		 69.37% 67.28% 65.32% 59.34% 70.30%
SG&A Expenses to Revenue		 8.06% 5.67% 5.99% 9.29% 9.37%
R&D to Revenue		 7.55% 4.93% 3.89% 3.19% 3.76%
Operating Expenses to Revenue		 17.96% 21.20% 19.76% 24.95% 26.28%
Earnings before Interest and Taxes (EBIT)		 3.08 3.17 3.39 4.26 1.79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 3.42 3.54 3.62 4.61 2.04
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 0.53 0.05 14.56 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.53 0.05 14.56 0.00
Price to Revenue (P/Rev)		 0.39 0.21 0.03 8.92 0.00
Price to Earnings (P/E)		 3.04 3.31 0.25 47.75 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 32.90% 30.17% 407.69% 2.09% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.11 0.00 30.78 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.02 0.00 8.59 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.26 0.00 87.62 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.29 0.00 94.74 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.44 0.00 135.76 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.59 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 322.87 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.00 0.17 0.40 0.64
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.46 -0.50 -0.53 -0.45
Leverage Ratio		 0.00 1.37 1.37 1.50 1.71
Compound Leverage Factor		 0.00 1.19 1.30 1.47 1.52
Debt to Total Capital		 0.00% 0.00% 14.64% 28.39% 38.91%
Short-Term Debt to Total Capital		 0.00% 0.00% 14.64% 28.39% 38.91%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% -0.66% -0.14%
Common Equity to Total Capital		 0.00% 100.00% 85.36% 72.26% 61.22%
Debt to EBITDA		 0.00 0.00 1.14 2.46 9.24
Net Debt to EBITDA		 0.00 0.00 -3.48 -3.35 -5.30
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 1.61 3.81 35.79
Net Debt to NOPAT		 0.00 0.00 -4.91 -5.19 -20.50
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 4.89 3.15 17.21 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% -0.50% -0.57%
Liquidity Ratios		 - - - - -
Current Ratio		 0.00 3.31 3.49 2.50 1.86
Quick Ratio		 0.00 1.96 2.82 2.06 1.49
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -6.06 -0.67 1.25 -5.14
Operating Cash Flow to CapEx		 13,626.76% 3,935.31% 2,992.71% -834.92% 43.80%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 615.60 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 611.08 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 1.83 1.47 1.19 0.83
Accounts Receivable Turnover		 0.00 9.31 6.30 5.52 5.72
Inventory Turnover		 0.00 3.84 4.40 5.45 5.76
Fixed Asset Turnover		 0.00 23.58 25.50 31.96 8.84
Accounts Payable Turnover		 0.00 5.73 6.56 8.71 9.28
Days Sales Outstanding (DSO)		 0.00 39.19 57.97 66.13 63.84
Days Inventory Outstanding (DIO)		 0.00 95.04 83.01 66.92 63.35
Days Payable Outstanding (DPO)		 0.00 63.71 55.67 41.90 39.33
Cash Conversion Cycle (CCC)		 0.00 70.52 85.31 91.15 87.86
Capital & Investment Metrics		 - - - - -
Invested Capital		 0.00 8.17 11 13 19
Invested Capital Turnover		 0.00 9.40 4.05 3.84 2.59
Increase / (Decrease) in Invested Capital		 0.00 8.17 3.23 1.72 5.66
Enterprise Value (EV)		 0.00 0.93 -11 404 0.00
Market Capitalization		 8.00 8.00 1.17 419 0.00
Book Value per Share		 $0.00 $0.11 $0.17 $0.18 $0.19
Tangible Book Value per Share		 $0.00 $0.11 $0.17 $0.18 $0.19
Total Capital		 0.00 15 28 40 48
Total Debt		 0.00 0.00 4.11 11 19
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -7.07 -13 -15 -11
Capital Expenditures (CapEx)		 0.04 0.04 0.10 0.14 6.63
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 6.13 9.61 10 9.55
Debt-free Net Working Capital (DFNWC)		 0.00 13 26 37 39
Net Working Capital (NWC)		 0.00 13 22 26 20
Net Nonoperating Expense (NNE)		 -0.97 -3.31 -3.20 -4.12 -2.05
Net Nonoperating Obligations (NNO)		 0.00 -7.07 -13 -15 -11
Total Depreciation and Amortization (D&A)		 0.35 0.36 0.23 0.35 0.24
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 15.97% 24.23% 21.76% 23.09%
Debt-free Net Working Capital to Revenue		 0.00% 34.39% 66.35% 78.69% 94.71%
Net Working Capital to Revenue		 0.00% 34.39% 55.98% 54.60% 49.18%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.02 $0.02 $0.01
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 145.14M 156.47M 156.55M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.02 $0.01
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 155.95M 156.47M 156.55M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 155.95M 156.55M 156.55M
Normalized Net Operating Profit after Tax (NOPAT)		 2.40 2.10 2.56 2.97 0.53
Normalized NOPAT Margin		 11.58% 5.48% 6.46% 6.33% 1.27%
Pre Tax Income Margin		 13.87% 7.15% 8.13% 8.90% 3.86%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 323.99 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 253.30 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 319.47 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 248.78 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 4.03%

Quarterly Metrics And Ratios for Jin Medical International

No quarterly metrics and ratios for Jin Medical International are available.


Financials Breakdown Chart

Jin Medical International Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Jin Medical International's financial year ends in September. Their financial year 2025 ended on September 30, 2025.

Jin Medical International's net income were at $2.57 million at the end of 2025, a 63.7% decrease from 2024, and a 23.7% decrease since 2021. View Jin Medical International's forecast to see where analysts expect Jin Medical International to go next.

Jin Medical International's total operating income in 2025 was $608.18 thousand, based on the following breakdown:
  • Total Gross Profit: $6.04 million
  • Total Operating Expenses: $10.87 million

Over the last 4 years, Jin Medical International's total revenue changed from $20.76 million in 2021 to $41.37 million in 2025, a change of 99.3%.

Jin Medical International's total liabilities were at $23.80 million at the end of 2025, a 38.0% increase from 2024, and a 317.2% increase since 2022.

In the past 3 years, Jin Medical International's cash and equivalents has ranged from $4.79 million in 2022 to $8.14 million in 2024, and is currently $7.46 million as of their latest financial filing in 2025.

Over the last 4 years, Jin Medical International's book value per share changed from 0.00 in 2021 to 0.19 in 2025, a change of 18.9%.


Related Companies

Financial statements for NASDAQ:ZJYL last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel